FDA approves Niktimvo for chronic graft-versus-host disease
Drug Discovery World
AUGUST 20, 2024
The major efficacy outcome measure was overall response rate (ORR) through Cycle 7 Day 1, where overall response included complete response or partial response according to the 2014 NIH Consensus Development Project on Response Criteria. ORR was 75% in the 79 patients treated with the recommended dosage.
Let's personalize your content